These results suggested that promoting the number of cytotoxic Tim‐3+ CD8+ T cells may be a promising strategy for effective anti‐tumour immune responses and that PTPN2 in immune cells may be a useful target for cancer immunotherapy.36 The gene discussed is HAVCR2; the disease is cancer.